about
Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairmentNeurofibromatosis 1 and multiple sclerosis.Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.Neurofibromatosis-related tumors: emerging biology and therapies.A search for evidence of somatic mutations in the NF1 gene.The impact of PET scanning on management of paediatric oncology patients.Late-onset optic pathway tumors in children with neurofibromatosis 1.Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1.Guidelines for the diagnosis and management of individuals with neurofibromatosis 1Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.Functional outcome measures for NF1-associated optic pathway glioma clinical trials.Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.Neurofibromatosis type 1 (NF1): diagnosis and management.Management of Guillain-Barré syndrome.Hippocampal involvement in identical twins with neurofibromatosis type 1.English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2.International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor.Visual function and optic pathway glioma: a critical response.An unusual case of hearing loss in a patient with neurofibromatosis type 1.A qualitative study of the impact of living with neurofibromatosis type 2.A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life.High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.Frequency of SMARCB1 mutations in familial and sporadic schwannomatosisConsensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Germline and somaticNF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs)What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiersArray-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath TumorPlasma exchange for Guillain-Barré syndromeSpinal neurofibroma presenting as atlanto-axial subluxation in von Recklinghausen neurofibromatosis'Phantom' typical absences, absence status and experiential phenomenaNeurofibromatosis 1The neurofibromatosesAutologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathyFocal inhibitory seizures: a cause of recurrent transient weakness
P50
Q30425761-7ED42F52-3826-4C79-ABB3-A13495917408Q33561323-3028CD1B-C4D5-4101-B160-63C8CF201E9DQ33591137-A7681D09-5417-4306-912C-C6D6BD210DC0Q33734114-6A3FA051-E2A0-4C85-8061-F91CE07C727DQ34577777-7F336BFC-9097-4CAA-8153-5739225FF534Q35218073-2CF73310-BA77-4731-BC60-B92CCB17C66EQ35433424-DD770343-42EF-4F9F-829A-4F702DDCBED5Q35854149-D0462A3A-3E85-47B0-88DB-75402D2CA7E9Q35959175-5BD48C4F-4805-40E2-B358-719EF066E0E8Q36172605-308F6593-5191-4102-9098-9259B6D5BC10Q36653938-31E55D0B-DBC9-4B61-B295-EB789B811FE1Q36771546-EE09F57B-F094-4F18-9152-B3E589F10CD0Q37536287-43D869D8-9557-4A8C-B50E-06B329B1E949Q38030473-8B31644E-3406-41B4-B573-B848DE34793BQ38127921-2AF7C858-BAC0-448F-A5AC-E131ED0D8BF5Q39693527-6E28D5A4-5353-41F7-B026-C98EA3EC1539Q43070919-6E47F513-7586-49AC-9EBF-9622B9C33870Q43623061-7B2B0600-DF31-4BC5-93C4-F7519D043852Q43917946-AB7457EB-A1DD-4DB5-BD22-35CF4CE4517EQ46190354-197D1EBD-90E4-4258-850D-26BBD009935EQ46854504-7ABDEC4E-1450-42E6-970C-6D26A4D3F550Q50431935-E5CC02AB-8964-456F-B6C6-B545CA56B28AQ50435399-90299883-A46C-44E0-B0B4-7515960A000DQ51890009-9F0694CA-83EF-4A40-90FB-E62892535962Q53068444-8F8161D7-A060-484E-A51F-1363F1600407Q53549151-736CC852-BCE9-4599-A01F-4A321378715AQ55470115-52E5941D-D26F-4352-B512-A1443F3F15B3Q55638662-01F717E6-AB2F-4F77-AC11-CD98BA712D9EQ57266550-FBABFBBC-BD25-4714-8F2B-DA87563EDA13Q57266579-231F3CE1-A1BC-4948-A0C3-F6CD58B97559Q57266693-54E21E17-85BB-4F21-B7E1-DC2239568E7EQ57657390-0C0CAECF-AF64-4825-A186-7CBAC809D49FQ61829389-0A601B98-8719-45D2-BD26-D9660E216241Q69232004-F08AC06E-EE71-4451-BACE-62D5783173D3Q69275465-1F5B603B-2316-4F6B-97A6-FAA9D0AD5F9BQ72373547-3C34D922-82DB-4998-A6B8-78971AE77AACQ80224253-30DE16DA-F33A-4229-9FE5-1B296362D520Q83821184-8A1F41CD-552A-40DE-BB08-E6FC2948DB4CQ84429786-EB05E2FE-8777-4EC0-86FA-AC62B457EECEQ85737413-CE74B27C-FB30-4E52-8546-29C362791EE1
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Ferner R
@ast
Ferner R
@es
Ferner R
@nl
Rosalie Ferner
@en
type
label
Ferner R
@ast
Ferner R
@es
Ferner R
@nl
Rosalie Ferner
@en
altLabel
Ferner R
@en
prefLabel
Ferner R
@ast
Ferner R
@es
Ferner R
@nl
Rosalie Ferner
@en
P31
P496
0000-0002-9169-4698